DDInter1247 DDInter1676
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Moxifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Moxifloxacin {u} (Compound) binds {v} (Gene) TOP2A
Moxifloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Moxifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Moxifloxacin {u} (Compound) causes {v} (Side Effect) Oedema
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium acetate
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Eribulin
Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Moxifloxacin (Compound) binds TOP2A (Gene)
Moxifloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Moxifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Moxifloxacin (Compound) causes Oedema (Side Effect)
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium acetate
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Moxifloxacin may lead to a major life threatening interaction when taken with Eribulin